Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 0075 • ACR Convergence 2021
Endothelial Cell-activating Antibodies in COVID-19
Hui Shi¹, Yu Zuo², Sherwin Navaz², Alyssa Harbaugh², Claire Hoy², Alex Gandhi², Gautam Sule², Srilakshmi Yalavarthi², Kelsey Gockman², Jacqueline Madison², Jintao Wang², Melanie zuo², Yue Shi³, Michael Maile², Yogendra Kanthi² and Jason Knight², ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Shanghai Sports School, Shanghai, China (People's Republic)
Background/Purpose: Patients with COVID-19 are at high risk for occlusion of vascular beds of all sizes. Considering endothelial cell activation has regularly been described as…
Abstract Number: 0076 • ACR Convergence 2021
Predicting the Transitions Between Lupus Anticoagulant Status and Thrombosis in SLE Using a Multi-state Markov Model
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Antiphospholipid syndrome (APS) is a significant cause of morbidity and mortality in patients with SLE and lupus anticoagulant (LAC) positivity is the best predictor…
Abstract Number: 0077 • ACR Convergence 2021
Association of Lupus Nephritis and Other Clinical Features with Antiphospholipid Antibody Positivity Among Patients with Systemic Lupus Erythematosus
Prarthana Jain, Jim Oates, Dulaney Wilson and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Antiphospholipid antibody (aPL) positivity is associated with elevated risk of thrombosis among patients with SLE, but other clinical associations are less well-known. The goal…
Abstract Number: 0078 • ACR Convergence 2021
Frequency and Clinical Characteristics of Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus: The Georgia Lupus Registry
Jinan al-naqeeb¹, Gaobin Bao², Cristina Drenkard² and S Sam Lim³, ¹Emory University, Decatur, GA, ²Emory University, Atlanta, GA, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Although APS was originally described in those with SLE, the epidemiology and clinical characteristics of secondary APS (2APS) has not been well described in…
Abstract Number: 0079 • ACR Convergence 2021
Association Between Preconception Complement Levels and Use of Hydroxychloroquine with Pregnancy Outcome in Patients with Primary Antiphospholipid Syndrome and Carriers of Antiphospholipid Antibodies: An International Multicenter Study
Daniele Lini¹, Cecilia Nalli², Laura Andreoli³, Francesca Crisafulli¹, Micaela Fredi¹, Maria Grazia Lazzaroni¹, Viktoria Bitsadze⁴, Antonia Calligaro⁵, Valentina Canti⁶, Roberto Caporali⁷, Francesco Carubbi⁸, Cecilia Chighizola⁹, Paola Conigliaro¹⁰, Fabrizio Conti¹¹, Caterina De Carolis¹², Teresa Del Ross⁵, Maria Favaro⁵, Maria Gerosa⁹, Annamaria Iuliano¹³, Jamilya Khizroeva⁴, Alexander Makatsariya⁴, Pier Luigi Meroni¹⁴, Marta Mosca¹⁵, Melissa Padovan¹⁶, Roberto Perricone¹⁰, Patrizia Rovere Querini⁶, Gian Domenico Sebastiani¹³, Chiara Tani¹⁷, Marta Tonello¹⁸, Simona Truglia¹¹, Dina Zucchi¹⁵, Franco Franceschini¹ and Angela Tincani¹⁹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ³University of Brescia, Brescia, Italy, ⁴Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia, ⁵Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, ⁶Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁷Policlinico S. Matteo University, Pavia, Italy, ⁸Department of Biotechnological and Applied Clinical Science, Rheumatology Unit, School of Medicine, University of L'Aquila, L'Aquila, Italy, ⁹University of Milan, Milan, Italy, ¹⁰Rheumatology, Allergology and Clinical Immunology, Department of "Medicina dei Sistemi", University of Rome Tor Vergata, Rome, Italy, ¹¹Lupus Clinic, Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Rome, Italy, ¹²Polymedical Center for Prevention of Recurrent Spontaneous Abortion, Rome, Italy, ¹³Rheumatology Unit, Azienda Ospedaliera San Camillo-Forlanini, Rome, Italy, ¹⁴Division of Rheumatology, ASST.G Pini, Department of Clinical Sciences and Community Health, University of Milan and Istituto Auxologico Italiano, Milan, Italy, ¹⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁶Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy, ¹⁷Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ¹⁸BSC, Rheumatology Unit, Department of Medicine, University of Padua, Padua, Italy, ¹⁹ASST Spedali Civili-University of Brescia, Gussago, Italy
Background/Purpose: APS is a rare autoimmune disease characterized by thrombotic events and/or pregnancy morbidities in the presence of confirmed positivity for aPL. Complement was demonstrated…
Abstract Number: 0080 • ACR Convergence 2021
One Point Increase in the Initial Damage as Measured by the Damage Index for Antiphospholipid Syndrome Predicts Mortality in a Multi-Ethnic Group of Thrombotic Antiphospholipid Syndrome Patients
Pedro Gaspar¹, Filipa Farinha², Zara Sayar³, Maria Efthymiou,⁴, Hannah Cohen³ and David Isenberg², ¹Department of Internal Medicine 2, University Hospital of Santa Maria, Lisbon, Portugal, ²Centre for Rheumatology, University College London, London, United Kingdom, ³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ⁴Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom
Background/Purpose: The chronic and recurrent nature of antiphospholipid syndrome (APS) leads to damage accrual that impairs long-term functional status and survival. The Damage Index for…
Abstract Number: 0081 • ACR Convergence 2021
Thrombin Generation Assay and Lupus Anticoagulant Identify Different Populations of Patients with Antiphospholipid Antibodies
Massimo Radin¹, Alice Barinotti¹, Irene Cecchi², Silvia Grazietta Foddai¹, Elena Rubini¹, Dario Roccatello¹, Elisa Menegatti¹ and Savino Sciascia¹, ¹University of Turin, Turin, Italy, ²University of Turin, Torino, Italy
Background/Purpose: Risk stratification in patients with antiphospholipid antibodies (aPL) remains a clinical challenge. We aim to evaluate the role of Thrombin Generation Assay (TGA) in…
Abstract Number: 0082 • ACR Convergence 2021
Association of Current Cigarette Smoking and Obesity with Antiphospholipid Antibodies and Thrombosis in 1216 International Patients Evaluated for Suspected Antiphospholipid Syndrome (APS)
Medha Barbhaiya¹, Deanna Jannat-Khah¹, Doruk Erkan¹, Karen Costenbader² and On Behalf of New APS Classification Criteria Development Case Collectors¹, ¹Hospital for Special Surgery, New York, NY, ²Brigham and Women's Hospital, Belmont, MA
Background/Purpose: Few studies have evaluated the role of environmental factors in APS. While antiphospholipid antibodies (aPL) may be induced by environmental stiumuli, e.g., viruses, cardiovascular…
Abstract Number: 0083 • ACR Convergence 2021
Cardiac Valve Surgery Outcomes in the Antiphospholipid Syndrome
Tali Eviatar¹, Stanley Niznik², Nancy Agmon-Levin² and Daphna Paran³, ¹Tel Aviv Sourasky Medical Center, Givataim, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel
Background/Purpose: Cardiac valve involvement in the APS is prevalent, necessitating valve surgery in about 5% of the patients. Data regarding valve surgery outcomes in APS…
Abstract Number: 0948 • ACR Convergence 2021
Immunometabolism of Neutrophils in Antiphospholipid Syndrome (APS)
Ajay Tambralli¹, Alyssa Harbaugh², Shanea Estes², Srilakshmi Yalavarthi², Claire Hoy², Gautam Sule² and Jason Knight², ¹University of Michigan, Ypsilanti, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: Neutrophil hyperactivity and neutrophil extracellular trap (NET) release (NETosis) appear to play roles in APS pathophysiology. Until recently, it was thought that neutrophils relied…
Abstract Number: 0069 • ACR Convergence 2021
First and Recurrent Thrombosis Risk After 3842 Patient-Years of Follow-Up: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (
Yasaman Ahmadzadeh¹, Danieli Andrade², Maria Tektonidou³, Vittorio Pengo⁴, Savino Sciascia⁵, Amaia Ugarte⁶, H. Michael Belmont⁷, Maria Gerosa⁸, Paul R Fortin⁹, Maria Angeles Aguirre¹⁰, Lanlan Ji¹¹, Tatsuya Atsumi¹², Hannah Cohen¹³, Guilherme Ramires de Jesus¹⁴, D. Ware Branch¹⁵, Angela Tincani¹⁶, Nina Kello¹⁷, Michelle Petri¹⁸, Esther Rodriguez-Almaraz¹⁹, Roberto Ríos-Garcés²⁰, Yu Zuo²¹, Bahar Artim-Esen²², Rohan Willis²³, Maria Laura Bertolaccini²⁴, Robert Roubey²⁵, Doruk Erkan¹ and on Behalf of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³FORZAFORTE HELLAS LTD, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵University of Turin, Turin, Italy, ⁶Hospital Universitario Cruces, Barakaldo, Spain, ⁷NYU School of Medicine, New York, NY, ⁸University of Milan, Milan, Italy, ⁹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁰IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹¹Peking University First Hospital, Beijing, China (People's Republic), ¹²Hokkaido University, Sapporo, Japan, ¹³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵University of Utah, Salt Lake City, UT, ¹⁶ASST Spedali Civili-University of Brescia, Gussago, Italy, ¹⁷Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Hospital Clínic de Barcelona, Barcelona, Spain, ²¹University of Michigan, Ann Arbor, MI, ²²Istanbul University School of Medicine, İstanbul, Turkey, ²³University of Texas Medical Branch, Galveston, TX, ²⁴King's College London, London, United Kingdom, ²⁵University of North Carolina, Chapel Hill, NC
Background/Purpose: APS ACTION “Registry” was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL)-positive patients with/without other systemic…
Abstract Number: 0949 • ACR Convergence 2021
Single-Cell RNA Sequencing of APS Skin Reveals Endothelial Pathology and Cellular Interactions
Hui Shi¹, Allison Billi², Rachael Wasikowski¹, Claire Hoy³, Kelsey Gockman¹, Lam Tsoi¹, Johann Gudjonsson², Pei-Suen Tsou¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²Department of Dermatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor
Background/Purpose: Although antiphospholipid syndrome (APS) regularly presents with discrete thrombotic events, many patients will also acquire organ damage over time secondary to occlusive neointimal formation…
Abstract Number: 0070 • ACR Convergence 2021
Pregnancy Outcomes of Antiphospholipid Antibody Positive Patients: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Zeynep Belce Erton¹, Ecem Sevim², Guilherme Ramires de Jesus³, Ricard Cervera⁴, Lanlan Ji⁵, Vittorio Pengo⁶, Amaia Ugarte⁷, Danieli Andrade⁸, Laura Andreoli⁹, Tatsuya Atsumi¹⁰, Paul R Fortin¹¹, Maria Gerosa¹², Yu Zuo¹³, Michelle Petri¹⁴, Savino Sciascia¹⁵, Maria Tektonidou¹⁶, Maria Angeles Aguirre¹⁷, D. Ware Branch¹⁸, Doruk Erkan¹ and on Behalf of APS ACTION¹, ¹Hospital for Special Surgery, New York, NY, ²Montefiore Medical Center - Wakefield Campus, Bronx, NY, ³Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁴Hospital Clinic Barcelona, Barcelona, Spain, ⁵Peking University First Hospital, Beijing, China (People's Republic), ⁶Padova University Hospital, Padova, Italy, ⁷Hospital Universitario Cruces, Barakaldo, Spain, ⁸Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁹University of Brescia, Brescia, Italy, ¹⁰Hokkaido University, Sapporo, Japan, ¹¹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹²University of Milan, Milan, Italy, ¹³University of Michigan, Ann Arbor, MI, ¹⁴Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁵University of Turin, Turin, Italy, ¹⁶FORZAFORTE HELLAS LTD, Athens, Greece, ¹⁷IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹⁸University of Utah, Salt Lake City, UT
Background/Purpose: APS ACTION Registry was created to study the natural course of disease over 10 years in persistently antiphospholipid antibody (aPL) positive patients with or…
Abstract Number: 0950 • ACR Convergence 2021
Mammalian Target of Rapamycin (mTOR) Pathway Assessment in Antiphospholipid Antibody Positive Patients with Livedo Reticularis/Racemosa
Ecem Sevim¹, Salma Siddique², Madhavi Latha Chalasani³, Susan Chyou⁴, William Shipman³, Orla O`Shea⁵, Oral Alpan⁶, Stephane Zuily⁷, Joanna Harp⁸, Theresa Lu³ and Doruk Erkan³, ¹Montefiore Medical Center - Wakefield Campus, Bronx, NY, ²Nemours/A.I.duPont Hospital for Children, Wilmington, DE, ³Hospital for Special Surgery, New York, NY, ⁴Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ⁵Analytical Microscopy Core Laboratory, Hospital for Special Surgery, New York, NY, ⁶O&O Alpan Medical Center, Vienna, VA, ⁷Nancy Academic Hospital, Vandoeuvre-ls-Nancy, France, ⁸Dermatology, Weill Cornell Medicine, New York, NY
Background/Purpose: Endothelial proliferation is a key finding in antiphospholipid antibody (aPL)-positive patients with microvascular disease. The mTOR pathway plays a role in the endothelial proliferation…
Abstract Number: 0071 • ACR Convergence 2021
Damage Accrual Measured by DIAPS in Antiphospholipid Antibody (aPL)-positive Patients: Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Gustavo Balbi¹, Yasaman Ahmadzadeh², Maria Tektonidou³, Vittorio Pengo⁴, Savino Sciascia⁵, Amaia Ugarte⁶, H. Michael Belmont⁷, Maria Gerosa⁸, Paul R Fortin⁹, Chary lopez-pedrera¹⁰, Lanlan Ji¹¹, Tatsuya Atsumi¹², Hannah Cohen¹³, Guilherme Ramires de Jesus¹⁴, D. Ware Branch¹⁵, Cecilia Nalli¹⁶, Nina Kello¹⁷, Michelle Petri¹⁸, Esther Rodriguez-Almaraz¹⁹, Giuseppe Barilaro²⁰, Jason Knight²¹, Bahar Artim-Esen²², Rohan Willis²³, Maria Laura Bertolaccini²⁴, Robert Roubey²⁵, Doruk Erkan², Danieli De Andrade¹ and on Behalf of APS ACTION², ¹University of São Paulo, São Paulo, Brazil, ²Hospital for Special Surgery, New York, NY, ³FORZAFORTE HELLAS LTD, Athens, Greece, ⁴Padova University Hospital, Padova, Italy, ⁵University of Turin, Turin, Italy, ⁶Hospital Universitario Cruces, Barakaldo, Spain, ⁷NYU School of Medicine, New York, NY, ⁸University of Milan, Milan, Italy, ⁹CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹⁰IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ¹¹Peking University First Hospital, Beijing, China (People's Republic), ¹²Hokkaido University, Sapporo, Japan, ¹³Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom, ¹⁴Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹⁵University of Utah, Salt Lake City, UT, ¹⁶ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ¹⁷Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY, ¹⁸Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁹Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁰Clínic Barcelona - Hospital Universitari, Barcelona, Spain, ²¹University of Michigan, Ann Arbor, MI, ²²Istanbul University School of Medicine, İstanbul, Turkey, ²³University of Texas Medical Branch, Galveston, TX, ²⁴King's College London, London, United Kingdom, ²⁵University of North Carolina, Chapel Hill, NC
Background/Purpose: Damage Index in APS (DIAPS) is a scoring system developed to assess long-term damage in thrombotic primary antiphospholipid syndrome (PAPS), which also correlates with…

« Previous Page
1
…
7
8
9
10
11
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].